First-in-human phase I dose escalation trial of the first-in-class tumor microenvironment modulator VT1021 in advanced solid tumors.

Devalingam MahalingamWael HarbAmita PatnaikAndrea J BullockRandolph S WatnickMelanie Y VincentJian Jenny ChenSuming WangHarold PestanaJudy ChaoJames MahoneyMichael CieslewiczJing Watnick

Published in: Communications medicine (2024)

VT1021 is safe and well-tolerated across all doses tested. RP2D has been selected for future clinical studies. PR and SD with tumor shrinkage are observed in multiple patients underscoring the single-agent potential of VT1021. Expansion studies in GBM, pancreatic cancer and other solid tumors at the RP2D have been completed and results will be communicated in a separate report.

Keyphrases

end stage renal disease
endothelial cells
ejection fraction
newly diagnosed
peritoneal dialysis
study protocol
clinical trial
prognostic factors
phase iii
open label
patient reported outcomes
phase ii
current status
pluripotent stem cells